Zoekresultaten - You searched for Patients

202 results

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Read more

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Read more

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Read more

Tau prevents synaptic transmission at early stage of neurodegeneration

Read more

Biocartis Group NV: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Read more

TiGenix opens US headquarters in Cambridge, MA

Read more

TiGenix Launches Global Phase III Trial for Cx601

Read more

eTheRNA immunotherapies advances In-Vivo mRNA Cancer Immunotherapy into first Oncology Clinical Studies

Read more

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Read more

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Read more

Celyad announces initiation of the SHRINK trial

Read more

Dosing of First Patient with investigational agent OMO-1

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

Metastatic breast cancers: Characterising the profile of metastases for improved treatment

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Read more

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

Galapagos reports first quarter 2017 results

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Read more

VIB: Shortage of progranulin is a frequent cause of frontotemporal dementia

Read more

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Read more

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Read more

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

Biocartis Group NV: Study demonstrating high performance of Idylla(TM) liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Read more

Celyad Announces First Quarter 2017 Business Update

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

Celyad obtains additional US patent for cancer treatment

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

Scientists give tumor-fighting cells a boost in battling bone marrow cancer

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Read more

SelectMDx to be Distributed Across Middle East by IPS Genomix

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

Read more

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

Read more

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Read more

Celyad Reports First Half 2017 Financial Results and Operational Progress

Read more

Mindbytes expands to North America to develop next generation serious medical games driven by artificial intelligence

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

Biocartis announces H1 2017 results

Read more

ThromboGenics Business Update - H1 2017

Read more

TiGenix strengthens US operations with senior appointments

Read more

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Read more

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

Scientists pinpoint surprising origin of melanoma

Read more

ThromboGenics Business Update - Q3 2017

Read more

GAMIAN-Europe & CMAST announce collaborative partnership

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

Read more

Ionis Pharmaceuticals licenses novel antisense drug for the treatment of centronuclear myopathy to dynacure

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

Mindbytes initiates oncology R&D program focused on patient empowerment and is selected as one of five finalists for Astellas Oncology C3 Prize®

Read more

Biocartis present at investor event VFB Happening this Saturday 25 March, Antwerp, BE

Read more

Novosanis receives Interreg CrossCare grant for its Colli-Pee™ device

Read more

Novosanis signs an agreement to provide MDxHealth a customized urine collection device

Read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

TiGenix reports 2016 full year results

Read more

New Study Shows MDxHealth's SelectMDx Test is Cost-Effective for Biopsy Selection

Read more

Specialized blood vessels enhance tumor-fighting immunotherapy

Read more

REVERSED BREXIT: £250 MILLION FOR BART DE STROOPER'S DEMENTIA RESEARCH

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Read more

MDxHealth Trading Update: January to April 2017

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

Bone Therapeutics Business Update for First Quarter 2017

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

VIB: Researchers identify nutrient metabolism that drives breast tumor metastasis

Read more

ThromboGenics Business Update - Q1 2017

Read more

ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

Read more

SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

Innovative software Moon autonomously diagnoses rare diseases within minutes

Read more

Cochlear acquires exclusive licence to Artificial Intelligence assistant

Read more

Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Read more

MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer

Read more

Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

Biocartis launches CE-marked IVD test for lung cancer

Read more

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Read more

QBD Webinar on validation of mobile apps

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

ConfirmMDx Featured in OncologyLive Magazine

Read more

ConfirmMDx Study Provides Further Validation of Epigenetic Risk Profile

Read more

Navigation and spatial memory: new brain region identified to be involved

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Read more

Bone Therapeutics announces H1 results for 2017

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Read more

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

Read more

2nd Symposium : « Introduction of the Next-Generation-sequencing technology in routine analysis in the Belgian healthcare »

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Read more

ONTOFORCE wins the EIT Venture Award 2017

Read more

argenx reports third quarter 2017 financial results and provides business update

Read more

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

MDxHealth Nine Month Trading Update

Read more

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

Read more

Bone Therapeutics Business Update for Third Quarter 2017

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

Count your blessings: Quantitative Microbiome Profiling

Read more

Celyad Announces Third Quarter 2017 Business Update

Read more

Symposium on Sepsis

Read more

Galapagos: Publication of the annual report

Read more

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Read more

Galapagos increases share capital through warrant exercises

Read more

Galapagos raises $338 million gross proceeds in a U.S. public offering

Read more

Galapagos announces launch of proposed public offering

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Read more

Galapagos announces capital increase

Read more

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

Read more

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Read more

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

Biocartis Group NV: Biocartis announces its new CEO

Read more

Biocartis Group NV: Results of the annual shareholders' meeting held on 12 May 2017

Read more

Galapagos to hold Annual R&D Update 2017 on 20 June

Read more

Galapagos creates new warrant plan

Read more

Researchers discover mechanism behind rapid smell source localization

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

Services

Read more

Daily Newsflash- 14/06/17

Read more

Daily Newsflash- 15/06/2017

Read more

Daily Newsflash- 27/06/17

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Daily Newsflash- 29/06/17

Read more

iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Read more

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

Read more

Celyad announces new agreements with Celdara medical and Dartmouth College

Read more

Interreg 2 Seas Project DERMA Industrial Matchmaking and Showcase Event

Read more

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Read more

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Read more

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

Read more

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Read more

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

Read more

Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

pi life sciences consultancy launches Music For Life-campaign to lift the taboo on young dementia

Read more

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this Fall

Read more

TiGenix to participate and present at key investor and business development meetings

Read more

Key Considerations in Health Care Product Development

Read more

Trainings - CONNECT / EDUCATE

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

Newly described process in Parkinson’s protein as a potential new therapy route

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

Press Release - Life Sciences & Biotechnology

Read more

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

Read more

Press Release - Life Sciences & Biotechnology

Read more

ThromboGenics Strengthens Leadership Team

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

MyCartis appoints Philippe Stas as CEO

Read more

Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

Read more